Latham & Watkins LLP advised Erasca on the offering. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca’s $100 Million Common Stock Offering
Erasca’s License Agreement With Novartis
Latham & Watkins advised Erasca on the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca’s $345 Million Initial Public Offering
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...